|
|
|
|
|
IAS 18 |
|
IFRS 15 |
IFRS 15 |
IAS 18 |
IAS 18 |
IFRS 15 |
||
|
Agreement |
Consideration |
Consideration |
Collaboration start date |
Outstanding balance in deferred income as at 31 December 2017 |
Deferred income reclassified from equity following adoption of IFRS 15 |
Outstanding balance in deferred income as at 1 January 2018 |
Revenue recognized, nine months ended 30 September 2018 |
Revenue recognized, nine months ended 30 September 2018 |
Revenue recognized, nine months ended 30 September 2017 |
Outstanding balance in deferred income as at 30 September 2018 |
||
|
|
(thousands of $) |
(thousands of €) |
|
(thousands of €) |
||||||||
|
||||||||||||
|
Revenue recognition of considerations received prior to 31 December 2017 |
||||||||||||
|
Gilead collaboration agreement for filgotinib – Upfront payment |
300,000 |
275,558 |
January 2016 |
187,449 |
– |
187,449 |
63,384 |
63,384 |
46,632 |
124,066 |
||
|
Gilead collaboration agreement for filgotinib – Subscription agreement(*) |
N.A. |
39,003 |
January 2016 |
26,532 |
– |
26,532 |
8,971 |
8,971 |
6,600 |
17,561 |
||
|
Servier collaboration agreement for osteoarthritis – License fee |
N.A. |
6,000 |
June 2010 |
5,362 |
(5,362) |
– |
– |
1,149 |
293 |
– |
||
|
AbbVie collaboration agreement for CF – Upfront payment |
45,000 |
34,001 |
September 2013 |
– |
14,872 |
14,872 |
4,761 |
– |
– |
10,111 |
||
|
Total upfront payments and license fees: |
|
219,343 |
9,510 |
228,853 |
77,116 |
73,504 |
53,526 |
151,737 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Gilead collaboration agreement for filgotinib – Milestone payments |
70,000 |
64,435 |
January 2016 |
– |
43,832 |
43,832 |
14,821 |
– |
9,354 |
29,011 |
||
|
AbbVie collaboration agreement for CF – Milestone payments |
77,500 |
68,310 |
September 2013 |
– |
29,878 |
29,878 |
9,565 |
– |
16,564 |
20,313 |
||
|
Total milestones: |
|
|
– |
73,710 |
73,710 |
24,387 |
– |
25,918 |
49,324 |
|||
|
Total: |
|
|
219,343 |
83,220 |
302,563 |
101,502 |
73,504 |
79,444 |
201,061 |
|||
|
Revenue recognition of considerations in the nine months ended 30 September 2018 |
||||||||||||
|
Novartis collaboration agreement for MOR106 – Upfront payment |
N.A. |
47,500 |
September 2018 |
|
|
|
47,500 |
|
|
– |
||
|
Total upfront payments and license fees: |
|
|
|
|
47,500 |
|
|
– |
||||
|
Gilead collaboration agreement for filgotinib – Milestone payments |
15,000 |
12,418 |
January 2016 |
|
|
|
6,827 |
|
|
5,591 |
||
|
AbbVie collaboration agreement for CF – Milestone payments |
10,000 |
8,548 |
September 2013 |
|
|
|
6,006 |
|
|
2,542 |
||
|
Servier collaboration agreement for osteoarthritis – Milestone payment |
N.A. |
9,000 |
June 2010 |
|
|
|
9,000 |
|
|
– |
||
|
Total milestones: |
|
|
|
|
|
21,833 |
|
|
8,133 |
|||
|
Total: |
|
|
|
|
|
69,333 |
|
|
8,133 |
|||
|
Grand total: upfront payments and license fees and milestones |
|
|
|
170,835 |
|
|
209,194 |
|||||